Tag: Cardiac arrhythmia

The US Food and Drug Administration has issued a boxed warning for methadone, highlighting several serious risks associated with its use, including fatal respiratory depression and life-threatening cardiac arrhythmias. It is crucial for patients and healthcare providers to understand what are the contraindications for methadone to ensure safe and effective treatment.

In 2001, the FDA issued a black box warning for droperidol due to its potential for causing QT prolongation and serious, sometimes fatal, arrhythmias. Therefore, specific patient populations and those with certain risk factors should not take droperidol, and its use is restricted to cases where other treatments are ineffective.

Digoxin has a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic one is small. Understanding what is a cardinal manifestation or symptom of digoxin toxicity is crucial for early detection and preventing severe outcomes.

While potentially rare, the mortality rate for Neuroleptic Malignant Syndrome (NMS), a severe reaction to antipsychotics, was historically over 30%, though increased awareness has significantly reduced this figure. Learning to identify what is a life threatening reaction to antipsychotics is crucial for anyone taking these medications or their caregivers to ensure rapid intervention and better outcomes.

In stable heart failure patients with early persistent atrial fibrillation, antiarrhythmic drug treatment was effective in nearly half of the patients [1.9.4]. A key part of this treatment involves understanding the question: **What is a class 3 medication?** These drugs are crucial for managing heart rhythm disorders.

In 2000, Janssen Pharmaceutica voluntarily stopped marketing the human version of cisapride (Propulsid) in the United States after hundreds of adverse event reports, including deaths, were linked to the drug's use. The key question, "Is cisapride still available?", now has a complex answer depending on the patient and species in question.

While medications are crucial for treating various conditions, a wide range of drugs can inadvertently trigger or exacerbate heart rhythm disorders like atrial flutter. Understanding **what medication can cause atrial flutter** is important for both patients and healthcare providers to manage risks effectively. These drug-induced arrhythmias are often the result of medication-induced changes in the heart's electrical conduction.

Cisapride (Propulsid®) was voluntarily withdrawn from the U.S. market in 2000 due to numerous reports of fatal cardiac arrhythmias. Understanding how to take cisapride is therefore critical, but only applies to the very few patients who still qualify for its use through a highly restrictive compassionate-use program.

In July 2000, following multiple reports of severe cardiac arrhythmias and fatalities, the GI motility drug Propulsid (cisapride) was voluntarily withdrawn from the U.S. market by its manufacturer. This action has led many to question, 'Can you still get Propulsid?', and the answer for most people is a definitive no.

According to the British National Formulary (BNF), concurrent use of domperidone and ondansetron is classified as a severe interaction and should be avoided. This critical precaution is due to the heightened and potentially fatal risk of a heart rhythm disorder when taking domperidone and ondansetron together.